The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab.
 
Samuel Funt
Stock and Other Ownership Interests - Kite, a Gilead company
 
Alexandra Snyder Charen
Employment - Third Rock Ventures
Consulting or Advisory Role - Third Rock Ventures
 
Erik Yusko
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
Patents, Royalties, Other Intellectual Property - Oxford Nanopore / Univ of Michigan
 
Marissa Vignali
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
 
Sharon Benzeno
Employment - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
 
Mariel Elena Boyd
No Relationships to Disclose
 
Meredith Maisie Moran
No Relationships to Disclose
 
Brooke Elizabeth Kania
No Relationships to Disclose
 
Catharine Kline Cipolla
No Relationships to Disclose
 
Ashley Marie Regazzi
No Relationships to Disclose
 
Harlan Robins
Employment - Adaptive Biotechnologies
Leadership - Adaptive Biotechnologies
Stock and Other Ownership Interests - Adaptive Biotechnologies
Patents, Royalties, Other Intellectual Property - Adaptive Biotechnologies
 
Gopa Iyer
No Relationships to Disclose
 
Jonathan E. Rosenberg
Stock and Other Ownership Interests - Illumina; Merck
Honoraria - UpToDate
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Johnson & Johnson; Lilly; Merck; Oncogenex; Onyx
Research Funding - Agensys; Genentech; Mirati Therapeutics; Oncogenex
Patents, Royalties, Other Intellectual Property - ERCC2 predicting cisplatin sensitivity
Travel, Accommodations, Expenses - Genentech/Roche
 
Dean F. Bajorin
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Fidia Farmaceutici S. p. A.; Genentech; Lilly; Merck; Novartis; Roche; Roche/Genentech
Research Funding - Amgen (Inst); dendreon (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Merck; Roche/Genentech